Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
IgM Antibody (DA4-4 (same as SA-DA4 or HB57)), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2342520.1MG
Description
IgM Monoclonal specifically detects IgM in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
IgM | |
Monoclonal | |
Unconjugated | |
PBS with 0.05% BSA. with 0.05% Sodium Azide | |
AGM1, DKFZp686I15196, DKFZp686I15212, FLJ00385, immunoglobulin heavy constant mu, MGC104996, MGC52291, MU, VH | |
Mouse | |
75 kDa | |
0.1 mg | |
Immunology | |
3507 | |
Human | |
Purified |
Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin) | |
DA4-4 (same as SA-DA4 or HB57) | |
Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1ug/ml, Immunohistochemistry-Frozen 0.5-1ug/ml | |
P01871 | |
IGHM | |
Heavy chain of human IgM | |
Protein A purified | |
RUO | |
Primary | |
Recognizes a protein of 75kDa, identified as mu heavy chain of human immunoglobulins. It does not cross-react with alpha (IgA), gamma (IgG), epsilon (IgE), or delta (IgD), heavy chains, T-cells, monocytes, granulocytes, or erythrocytes. This MAb is useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. The most common feature of these malignancies is the restricted expression of a single heavy chain class. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is clonal and therefore malignant. | |
Store at 4C. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction